The Company: Qmetis is a medical informatics company imagining, designing, building, and delivering point-to-point, evidence-based, decision-support software tools, now or shortly, for dozens of medical conditions to hospitals around the United States and, in the months ahead, globally.
The Reason: Evidence-based medicine is a systematic approach to medicine in which doctors, hospitals, and other health care professionals use the best available scientific evidence from clinical research to help make decisions about the care of individual patients. The literature is clear now that adherence to evidence-based treatment guidelines can change patient outcomes.
The Solutions: Qmetis’ products, the QmetisQx platform, take hundreds of pages of the latest evidence-based literature and condense that literature down to a fast, simple, flawless, always current, bedside decision-support software tool, ensuring that, at a minimum, the clinical team is aware of the latest treatment recommendations for every patient, during every shift.
The Platform: Qmetis has built and commercialized software solutions for adult traumatic brain injury, pediatric traumatic brain injury, concussion, and ischemic stroke. Development is now underway on the next series of solutions from Qmetis for spine surgery (SpineQx), antimicrobial stewardship (InfectionQx), and maternal health and mortality (MaternityQx).
Performance (Financial): February 2025. Qmetis has shown consistent revenue growth over the past five years with increasing profitability.
In February of 2025, Qmetis has:
• Four active products (TBI [adult and pediatric], Concussion, Ischemic Stroke)
• Three products in development (Spine, Infection, Maternity)
• 2025 state agreements for $3.2M
•Projected 2025 Revenues of $1.9M
• Established ongoing discussions with four additional states, totaling approximately $3M in additional potential 2025/2026 revenue.
The QFund1. Qmetis is looking to raise additional growth capital, in its Series A Round, via the QFUND1, of between $500K and $1M. This round will accelerate the Company's product development, onboard our first full-time dedicated sales and marketing executives, and advance discussions with international partners and opportunities.
Ready to Ask For Funding for your company?
Post a Funding Request